Myriad Genetics and Flatiron Health Collaborate to Expand Access to Genetic Testing Through EMR Integration

QIAGEN and Illumina Unveil New Solutions to Advance Liquid Biopsy and Next-Generation Sequencing

The Role of Biobanks in Advancing Precision Medicine

AstraZeneca and Daiichi Sankyo's Enhertu Secures Conditional Approval in China for HER2-Mutated NSCLC Treatment

SkylineDx Presents Breakthrough Data from Largest Melanoma Genomic Assay Trial at SMR Annual Meeting

Clario and PathAI Join Forces to Streamline GI Clinical Trials with Integrated Solutions

FDA Approves FoundationOne® Liquid CDx as Companion Diagnostic for Itovebi™ (inavolisib) to Identify Hormone Receptor-Positive, HER2-Negative Breast Cancer Patients with PIK3CA Mutation

Roche’s VENTANA CLDN18 (43-14A) RxDx Assay for Identifying Gastric and GEJ Cancer Patients Receives CE Mark Approval

Tempest and Roche Partner to Advance Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Singapore to Expand MediShield Life Coverage for Precision Medicine and Strengthen Genetic Data Protections

Bayer and MOMA Therapeutics Partner to Advance Precision Oncology Therapies

DermTech's Non-Invasive Genomic Testing Shows Promise in Differentiating Melanoma from Atypical Moles

Velsera and Diagnostic Longwood Partner to Accelerate Precision Medicine in Spain and Portugal

Aurigene Oncology Reports Promising Phase 1 Results for India’s First CAR-T Cell Therapy in Multiple Myeloma

Agilus Diagnostics Launches Pharmacogenomics Testing Service to Revolutionize Personalized Medicine

Home
/
update
/
details

Breakthrough Gene Therapy Trial Grants Deaf Children Hearing in Both Ears

NextEdge Admin

06 Jun 2024

3 min 54 sec

In a study published in Nature Medicine, the remarkable outcomes of a groundbreaking gene therapy trial conducted by doctors at Fudan University in Shanghai were detailed. The trial aimed to address the profound impact of hearing loss in five children born deaf due to inherited genetic mutations disrupting the production of a crucial protein essential for auditory signal transmission from the ear to the brain. By administering gene therapy to both ears of the children, aged between one and 11, the doctors sought to restore their hearing abilities, enabling them to participate in conversations and discern the direction of sounds.

Using an inert virus to deliver functional copies of the faulty gene, Otof, into the inner ear, the therapy facilitated the production of the vital protein, otoferlin, necessary for hearing. Within weeks of the treatment, the children exhibited significant improvements. They could locate the sources of sounds, recognize speech even in noisy environments, and engage with auditory stimuli in ways they couldn't before.

Dr. Zheng-Yi Chen of Massachusetts Eye and Ear, a co-leader of the trial, described the results as "astounding," highlighting the continued dramatic progress in the children's hearing abilities. Video footage showcased the transformation, with instances of children responding to their names, dancing to music, and demonstrating comprehension and speech capabilities after weeks of the therapy.

This landmark achievement, documented in Nature Medicine, underscores the potential of gene therapy in addressing congenital hearing loss caused by genetic anomalies. It signifies a significant step forward in understanding and treating this debilitating condition, offering hope to millions worldwide who grapple with hearing impairments of various origins.

While the therapy shows immense promise, further research, as detailed in the Nature Medicine publication, is crucial to comprehensively assess its long-term benefits and potential risks. Challenges such as prolonged surgical durations and heightened immune responses necessitate careful consideration. Nonetheless, researchers remain optimistic about expanding the scope of the trial to include other genetic and non-genetic causes of deafness, with the ultimate goal of restoring hearing regardless of its nature.

This groundbreaking achievement, documented in Nature Medicine, follows similar strides in gene therapy for hearing loss, exemplified by recent cases worldwide. Prof. Manohar Bance, chief investigator of a similar trial in the UK, hailed these advancements as ushering in a new era in the treatment of deafness, offering hope and possibility to millions globally.